97 related articles for article (PubMed ID: 31282227)
1. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
2. Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.
González J; Quiroga M; Escudero-Vilaplana V; Collado-Borrell R; Herranz-Alonso A; Sanjurjo Sáez M
Expert Opin Drug Saf; 2018 Jun; 17(6):553-572. PubMed ID: 29781751
[TBL] [Abstract][Full Text] [Related]
3. Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.
Casadei Gardini A; Tenti E; Masini C; Nanni O; Scarpi E; Valgiusti M; Restuccia S; Gallani ML; Palazzini S; Bianchini E; Menozzi S; Maugeri A; Amadori D; Minguzzi M; Frassineti GL
Oncotarget; 2016 Jun; 7(26):40719-40724. PubMed ID: 27119511
[TBL] [Abstract][Full Text] [Related]
4. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Jiménez RR; Peinado II; Herranz-Alonso A; Sanjurjo-Sáez M
Am J Health Syst Pharm; 2020 Aug; 77(17):1393-1402. PubMed ID: 32620958
[TBL] [Abstract][Full Text] [Related]
5. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C; Escudero-Vilaplana V; Collado-Borrell R; Giménez-Manzorro Á; Ribed A; Marzal-Alfaro B; Revuelta-Herrero JL; Gonzalez-Haba E; Herranz A; Sanjurjo M
Expert Opin Drug Saf; 2022 Jan; 21(1):107-119. PubMed ID: 34357828
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents.
Escudero-Vilaplana V; Ribed A; Romero-Jimenez RM; Herranz-Alonso A; Sanjurjo-Saez M
Eur J Cancer Care (Engl); 2017 May; 26(3):. PubMed ID: 26872286
[TBL] [Abstract][Full Text] [Related]
8. Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Hoyo-Muñoz A; Gimenez-Manzorro A; Calles A; Osorio S; Herranz-Alonso A; Sanjurjo-Sáez M
Expert Opin Drug Saf; 2020 Aug; 19(8):1041-1048. PubMed ID: 32529857
[TBL] [Abstract][Full Text] [Related]
9. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Del Monte-Millán M; Hoyo-Muñoz A; Gómez Martínez-Sagrera P; Revuelta-Herrero JL; Marzal-Alfaro B; Gonzalez-Haba E; López-Tarruella Cobo S; Jerez Gilarranz Y; Herranz A; Sanjurjo M; Martin M
Support Care Cancer; 2021 Aug; 29(8):4673-4681. PubMed ID: 33506273
[TBL] [Abstract][Full Text] [Related]
10. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
12. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.
Ramos-Ruperez E; Escudero-Vilaplana V; Ruiz-Briones P; Collado-Borrell R; Villanueva-Bueno C; Revuelta-Herrero JL; González-Haba E; Garcia-Gonzalez X; Ibañez-Garcia S; Perez-Ramirez S; Zatarain-Nicolás E; Herranz A; Sanjurjo M
Front Oncol; 2023; 13():1220305. PubMed ID: 37692846
[TBL] [Abstract][Full Text] [Related]
13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
14. A pharmacovigilance system for treatment access and medical donation programs: The Max Foundation experience.
Novakowski AK; Garcia-Gonzalez P; Wrigglesworth M; Stergachis A
Global Health; 2018 Jul; 14(1):76. PubMed ID: 30053910
[TBL] [Abstract][Full Text] [Related]
15. Pharmacists' perceived knowledge of and confidence in dispensing oral antineoplastic agents.
Dayer L; Dunn E; Pace A; Flowers S
J Am Pharm Assoc (2003); 2016; 56(2):141-4.e2. PubMed ID: 27000164
[TBL] [Abstract][Full Text] [Related]
16. How adverse events and permanent medication stoppages affect changes in patients' beliefs about oral antineoplastic agents.
Marshall VK; Given CW; Sikorskii A; Given BA; Lehto RH
Support Care Cancer; 2020 Jun; 28(6):2589-2596. PubMed ID: 31529159
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
18. Photo elicitation, an approach to better understanding the patient experience with OAAs: pilot study and future implications.
Manojlovich M; Blok A; Wright N; Azhari E; Farris KB; Friese CR; Mackler E; Titler M; Byrnes M
Support Care Cancer; 2023 Oct; 31(12):652. PubMed ID: 37878093
[TBL] [Abstract][Full Text] [Related]
19. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.
Collado-Borrell R; Escudero-Vilaplana V; Romero-Jiménez R; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Sáez M
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2319-30. PubMed ID: 27316629
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
